-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The role of tramadol in current treatment strategies for musculoskeletal pain
(2312) Views (806) Full article downloads
Authors: Stephan A Schug
Published Date November 2007
Volume 2007:3(5) Pages 717 - 723
DOI: http://dx.doi.org/10.2147/TCRM.S
Stephan A Schug
Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia and Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Western Australia
Abstract: Non-selective and cyclooxygenase-2 (COX-2) selective non-steroidal antiinflammatory drugs (NSAIDs) have been the mainstay of treatment for musculoskeletal pain of moderate intensity. However, in addition to gastrointestinal and renal toxicity, an increased cardiovascular risk may be a class effect for all NSAIDs. Despite these safety risks and the acknowledged ceiling effect of NSAIDs, many doctors still use them to treat moderate, mostly musculoskeletal pain. Recent guidelines for treating osteoarthritis and low back pain, issued by numerous professional medical societies, recommend NSAIDs and COX-2 inhibitors only in strictly defined circumstances, at the lowest effective dose and for the shortest possible period of time. These recent guidelines bring more focus to the usage of paracetamol and opioids. But opioids still remain under-utilized, although they are effective with minimal organ toxicity. In this setting, the atypical, centrally acting analgesic tramadol offers important benefits. Its multimodal effect results from a dual mode of action, ie, opioid and monoaminergic mechanisms, with efficacy in both nociceptive and neuropathic pain. Moreover, fewer instances of side effects such as constipation, respiratory depression, and sedation occur than with traditional opioids, and tramadol has been prescribed for 30 years for a broad range of indications. Tramadol is now regarded as the first-line analgesic for many musculoskeletal indications. In conclusion, it is recommended to better implement the more recent guidelines focusing on pain management and consider the role of tramadol in musculoskeletal pain treatment strategies.
Keywords: musculoskeletal pain, osteoarthritis, chronic low back pain, opioids, NSAIDs, coxibs, tramadol, multi-modal
Readers of this article also read:
Editorial Foreword || FREE PAPER ||
Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas
Pupillography of automated swinging flashlight test in amblyopia
Drug design with Cdc7 kinase: a potential novel cancer therapy target
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
ABO and rhesus blood group distribution in Kurds
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
7-Nitroindazole and its rapidly emerging role in opioid pain management and withdrawal
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




